Jonah Feldman | Authors


Minimal Difference in Efficacy Shown for Immunotherapy Combos in Poor-Performance Metastatic RCC

June 17, 2022

Following a study of frontline pembrolizumab plus axitinib or nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma, investigators recommended that prospective real-world studies are needed to confirm the results.